STOCKHOLM, Nov. 6, 2019 /PRNewswire/ -- IRLAB announced
today that drug candidates IRL942 and IRL1009 have been granted
composition of matter patents in the US and Europe from respective authorities. The
preclinical drug candidates are currently undergoing preparatory
steps to meet the regulatory requirements for obtaining permission
to conduct clinical phase I studies. Securing the intellectual
property rights is an important step in protecting the results of
the company's research and strengthens the projects' position and
commercial potential.
Drug candidates IRL942 and IRL1009 stem from IRLAB's P001
research program and are derived from the proprietary research
platform ISP. IRL942 and IRL1009 are intended for treatment of
mental and cognitive decline as well as declining motor skills
linked to neurodegenerative diseases and ageing. In several
recently conducted preclinical studies, the drug candidates' show
increased nerve cell signaling and improved cognition in behavioral
studies.
Nicholas Waters, CEO at IRLAB,
commented "Being granted patents for IRL942 and IRL1009 is a
significant demonstration of the power of innovation that lies
within our research platform ISP. Independently, two of the world's
key patent authorities have deemed that also these ISP derived
candidates fulfill criteria such as novelty, inventive step and
industrial applicability."
The US Patent and Trademark Office (USPTO) and its counterpart
the European Patent Office (EPO) are the authorities having granted
patents for the drug candidates IRL942 and IRL1009.
For further information
Nicholas Waters
CEO
Phone: +46-730-75-77-01
E-mail: nicholas.waters@irlab.se
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irlab-therapeutics-ab/r/irlab-s-drug-candidates-irl942-and-irl1009-have-been-granted-patents-in-the-us-and-europe,c2955072
The following files are available for download:
https://mb.cision.com/Main/15440/2955072/1136629.pdf
|
Release
|